Skip to main content
. 2019 Oct 31;17(1):235–242. doi: 10.1007/s13311-019-00796-3

Fig. 4.

Fig. 4

MOG and NMDAR antibodies in IVIg preparations. (A, B) Immunofluorescent images (× 40 magnification) show a MOG-positive control serum using in-house MOG CBA (A) compared to non-specific binding of IVIg (B). (C, D) Immunofluorescent images (× 20 magnification) of an NMDAR-positive control serum using commercial NMDAR CBA (C) compared to non-specific binding with IVIg (D)